Integrative Cancer Therapies最新文献

{"title":"JI017 Sensitizes EGFR-T790M NSCLC to Erlotinib by Extinguishing the STAT3-Survivin Axis.","authors":"Daeun Kim, Young-Ha Kim, Gaeun Choi, Chunhoo Cheon, Seong-Gyu Ko","doi":"10.1177/15347354261475694","DOIUrl":"10.1177/15347354261475694","url":null,"abstract":"<p><p>IntroductionFirst-generation EGFR-TKIs in NSCLC frequently lose efficacy as a result of the secondary EGFR-T790M mutation and a \"persistent-STAT3\" prosurvival pathway that sustains STAT3-survivin signaling in the face of EGFR inhibition. Preclinical evidence demonstrates that phytochemicals in the JI017 herbal formulation (2:1:1, <i>Angelica gigas</i>: processed <i>Aconitum carmichaeli</i>: <i>Zingiber officinale</i>) can reinstate erlotinib sensitivity in T790M-positive NSCLC, and relevant molecular mechanisms have been examined.MethodsAnti-proliferative activities were evaluated in A549 (EGFR-WT), HCC827 (EGFR Δ19), and H1975 (EGFR L858R/T790M) cells utilizing MTT assays, colony formation, and Annexin V/7-AAD flow cytometry. Mechanistic analyses included immunoblotting for p-EGFR (Tyr1068/1173), p-JAK2, p-STAT3 (Tyr705), PARP, Bcl-2, survivin, and AXL, complemented by RT-qPCR for BIRC5 and AXL transcripts. Drug interaction effects were determined using the Chou-Talalay combination index (CompuSyn). Anti-tumor efficacy was assessed in H1975 xenografts treated for 14 days with vehicle, JI017, erlotinib, or combination therapy; tumors underwent H&E staining and IHC for p-STAT3, survivin, and Ki-67.ResultsJI017 inhibited proliferation in all NSCLC cell lines tested, showing greatest effectiveness in H1975, where it triggered PARP cleavage and suppression of Bcl-2 and survivin expression. In H1975, co-treatment with JI017 and erlotinib led to synergistic growth inhibition, eradicated colony growth, and significantly elevated apoptotic cell populations compared to single treatments. While erlotinib alone reduced p-EGFR and p-JAK2, it left p-STAT3 largely unaltered, reflecting persistent-STAT3 activity. The combination regimen abrogated p-STAT3, further lowered p-EGFR and p-JAK2 levels, diminished BIRC5 mRNA, and decreased both AXL protein and transcript levels. In vivo, the drug combination achieved sustained tumor stasis relative to controls or monotherapy; combination group tumors displayed widespread necrosis and substantial decreases in p-STAT3, survivin, and Ki-67.DiscussionThese data support the suppression of STAT3-survivin as the primary mechanism by which JI017 sensitizes EGFR-T790M models to erlotinib. The consistent down-regulation of AXL indicates the inhibition of an AXL-mediated bypass that may maintain STAT3 signaling during EGFR blockade, although causality has yet to be confirmed. The marked in-vivo tumor inhibition without observable toxicity underscores the translational promise as a low-toxicity therapeutic adjunct.ConclusionsJI017 restores erlotinib sensitivity in EGFR-T790M NSCLC by inhibiting STAT3-survivin signaling and possibly reducing AXL-mediated resistance, resulting in durable antitumor effects both in vitro and in vivo. Additional preclinical studies and early-phase clinical assessment of JI017 in combination with erlotinib are justified.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354261475694"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13438235/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148669430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on: Efficacy and Safety of Shenyi Capsule (Ginsenoside Rg3) as Adjuvant Therapy for Cancer: An Overview of Systematic Reviews and Meta-Analyses.","authors":"Zhishuang An","doi":"10.1177/15347354261439130","DOIUrl":"10.1177/15347354261439130","url":null,"abstract":"","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354261439130"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13153527/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147770624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of Acupuncture and Moxibustion for Non-Small Cell Lung Cancer (NSCLC) Patients Undergoing Standard Treatment: A Systematic Review and Meta-Analysis.","authors":"Dong-Hyeon Kim, Mi-Sun Park, Keon-Jun Lee, Jong-Ha Kwon, Ye-Jin Jin, So-Jung Park","doi":"10.1177/15347354261419716","DOIUrl":"10.1177/15347354261419716","url":null,"abstract":"<p><strong>Background: </strong>Lung cancer is the leading cause of cancer-related mortality, with non-small cell lung cancer (NSCLC) accounting for 80% to 85% of cases. While surgery and chemotherapy are primary treatments, their side effects-such as nausea, vomiting, and immunosuppression-significantly impact quality of life (QoL). Acupuncture and moxibustion, commonly used in Traditional Asian Medicine (TAM), are proposed to alleviate these effects, though their efficacy in NSCLC remains uncertain. This systematic review and meta-analysis evaluated their impact on QoL, chemotherapy-induced nausea and vomiting (CINV), and immune function in NSCLC patients.</p><p><strong>Methods: </strong>Nine databases (PubMed, Embase, Cochrane Library, CNKI, OASIS, ScienceON, KISS, KMBASE, and RISS) were searched for randomized controlled trials (RCTs) published until April 2025. RCTs comparing acupuncture or moxibustion with standard care in NSCLC patients were included. Primary outcomes were QoL (QLQ-C30, KPS); secondary outcomes included CINV and immune markers (CD3, CD4, CD8, CD4/CD8 ratio, TNF-α). Data were analyzed using Review Manager 5.4, and risk of bias was assessed using the Cochrane RoB tool.</p><p><strong>Results: </strong>Thirty-nine RCTs (N = 3610) were included. Acupuncture and moxibustion significantly improved QoL (QLQ-C30 MD = 12.39; KPS MD = 8.22; both <i>P</i> < .00001), reduced CINV incidence (RR = 0.32, <i>P</i> < .00001), and enhanced symptom relief (RR = 1.16, <i>P</i> < .00001). Immune function markers, including CD3 (MD = 7.20, <i>P</i> = .0002), CD4 (MD = 4.89, <i>P</i> = .0003), and the CD4/CD8 ratio (MD = 0.22, <i>P</i> < .00001), were significantly increased, while TNF-α levels decreased (MD = -11.05, <i>P</i> = .04).</p><p><strong>Conclusion: </strong>Acupuncture and moxibustion improve QoL, reduce CINV, and modulate immune function in NSCLC, supporting their complementary role.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354261419716"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12924929/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146226612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Lentinula edodes</i> in Cancer Treatment: A Systematic Review and Meta-Analysis.","authors":"Byeong Seok Sohn, In Sil Choi, Soo Young Kim, Young Il Kim, Chi Hoon Maeng, Youngduk Seo, Youn Ju Lee, Wonyoung Jung, Seok Jae Huh, Sun Young Rha, Jung Hye Kwon","doi":"10.1177/15347354261483632","DOIUrl":"10.1177/15347354261483632","url":null,"abstract":"<p><p><i>Lentinula edodes</i> extracts are used by cancer patients as alternative or complementary therapies; however, no systematic review has evaluated their actual benefits. We searched several databases (Medline, Embase, Cochrane Library, CINAHL, AMED, and KoreanMed) and included studies comparing groups receiving <i>L. edodes</i> extracts alongside standard treatment with those receiving standard treatment alone. A total of 22 trials involving 1,723 cancer patients were included. Of these, 13 were randomized controlled trials (RCTs) and nine were controlled non-randomized trials (NRTs). In the analysis of the 13 RCTs, the <i>L. edodes</i> group showed a better response rate than the control group (odds ratio, 1.45; 95% confidence interval [CI], 1.01-2.07; <i>P</i> = 0.04). However, there was no significant difference in overall survival between the two groups (hazards ratio, 0.66; 95% CI, 0.34-1.28; <i>P</i> = 0.22). There was also no difference in the incidence of hematological or non-hematological adverse events (AEs) between the groups. Similarly, no significant difference in overall quality of life (QoL) was observed (standard mean difference, 0.23; 95% CI [-0.16, 0.62]; <i>P</i> = 0.25). In the nine NRTs, the <i>L. edodes</i> group demonstrated favorable outcomes in tumor response and QoL (<i>P</i> < 0.05). This review found that <i>L. edodes</i> extracts were associated with improved tumor response. However, these results have many limitations and do not translate into improved survival. Additionally, no differences were found in AEs or QoL. Overall, the evidence does not support clear recommendations, and more high-quality, well-designed randomized trials are needed.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354261483632"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13519233/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148828066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acupuncture and Related Therapies for Breast Cancer-Related Symptoms: An Evidence Map.","authors":"Lin Ang, Ji Hee Jun, Changsop Yang, Myeong Soo Lee, Tae-Young Choi","doi":"10.1177/15347354261490583","DOIUrl":"10.1177/15347354261490583","url":null,"abstract":"<p><p>BackgroundBreast cancer is the most frequent malignancy among women worldwide. Despite advances in medical treatment, many survivors experience distressing symptoms and therapy-related side effects that impair quality of life. Acupuncture-related therapies are increasingly employed as supportive care strategies, yet their evidence base remains fragmented.ObjectiveTo construct an evidence map of systematic reviews (SRs) and meta-analyses evaluating acupuncture and related therapies for breast cancer-related symptoms.MethodsSearches were performed in PubMed, Embase, and Cochrane Database of Systematic Reviews, China National Knowledge Infrastructure (CNKI), Wanfang, Research Information Service System (RISS), Oriental Medicine Advanced Search Integrated System (OASIS), and Korean Studies Information Services System (KISS) from inception to April 24, 2025. Eligible SRs included breast cancer populations, any acupuncture-related intervention, and reported outcomes relevant to symptom management or treatment side effects. Data extraction included bibliographic details, intervention type, outcomes, number of studies, sample size, effect direction, and methodological quality (AMSTAR-2). Evidence was synthesized descriptively and presented using heatmaps.ResultsA total of 47 SRs with meta-analysis were included, covering 11 distinct symptom domains and 6 categories of interventions. The most frequently studied outcomes were hot flashes (n=9), general supportive care during chemotherapy (n=9), lymphedema (n=7), general side effect management (n=6), and aromatase inhibitor-associated arthralgia (n=4). The most common interventions were acupuncture (n=17), acupuncture combination therapies (n=16), and acupoint injection (n=9). Across the included SRs, 20 reported positive effects, 23 were mixed, and 4 reported no clear evidence of benefit. Only 8 of 47 SRs achieved moderate confidence, and none were rated high, indicating widespread methodological limitations across the evidence base (29 low, 10 critically low).ConclusionAcupuncture and related therapies are widely studied as supportive care strategies for breast cancer-related symptoms with promising evidence. However, the majority of SRs are of low methodological quality. High-quality trials and rigorously conducted systematic reviews are needed to strengthen the evidence base, reduce redundancy, and guide integrative oncology practice.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354261490583"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149080643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Thanchonnang et al - From Efficacy to Implementation - Critical Insights for Clinical Practice.","authors":"Severin Schricker, Felix Breßmer, Mark Dominik Alscher, Claudia Löffler, Holger Cramer, Marcela Winkler","doi":"10.1177/15347354251410184","DOIUrl":"10.1177/15347354251410184","url":null,"abstract":"","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"24 ","pages":"15347354251410184"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12877485/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145810053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction Notice: Dihydromyricetin Exhibits Antitumor Activity in Nasopharyngeal Cancer Cell Through Antagonizing Wnt/β-Catenin Signaling.","authors":"","doi":"10.1177/15347354251364601","DOIUrl":"10.1177/15347354251364601","url":null,"abstract":"","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"24 ","pages":"15347354251364601"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12308103/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144730298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Intracranial Progression-Free Survival in Lung Cancer Brain Metastases Extended Beyond 50 Months with Gubenxiaoyi Formula (GBXY): A Groundbreaking Case Study.","authors":"Zhengzheng Yang, Haiming Li, Lei Chen, Shujiao Li, Dong Chen, Taicheng Lu, Tongjing Ding, Ruiyang Han, Peiyu Cheng, Xiaomin Wang","doi":"10.1177/15347354241313334","DOIUrl":"10.1177/15347354241313334","url":null,"abstract":"<p><strong>Background: </strong>The prevalence of brain metastases (BM) in lung cancer patients is notably high and is associated with poor prognoses. The efficacy of standard treatment regimens in improving intracranial progression-free survival (IPFS) for lung cancer BM is markedly limited. While traditional Chinese medicine (TCM) has been effective in enhancing the quality of life and prognosis of lung cancer patients, its efficacy in treating BM remains unreported.</p><p><strong>Case presentation: </strong>Here, we present a case of a middle-aged female with lung cancer BM, whose condition was assessed as progressive post-standard treatment including two local surgeries (both involving resection of cerebellar space-occupying lesions), stereotactic radiotherapy, chemotherapy and EGFR-TKIs. Subsequently, she underwent treatment with the traditional Chinese herbal formula gubenxiaoyi (GBXY). The patient was treated with GBXY for a total duration of 55 months. After treatment, a significant reduction of about 50% in intracranial lesions was observed, accompanied by an extension of both Intracranial Progression-Free Survival (IPFS) and Cognitive Deterioration-Free Survival (CDFS) exceeding 50 months.</p><p><strong>Conclusion: </strong>These results demonstrate that in patients with lung cancer brain metastases (BM) unresponsive to standard treatments, GBXY not only has the potential to effectively prolong IPFS and decelerate cognitive decline, but may also contribute to a reduction in intracranial tumor burden. This suggests that GBXY could be a promising therapeutic option that warrants further investigation.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"24 ","pages":"15347354241313334"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11780649/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143065465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Trichosanthes kirilowii</i> Maxim. and Bioactive Compound Cucurbitacin D Alleviate Cisplatin-Induced Peripheral Neuropathy In Vitro and In Vivo.","authors":"Sooyeon Kang, Gaeun Choi, Daeun Kim, Hogeol Kim, Chunhoo Cheon, Seong-Gyu Ko","doi":"10.1177/15347354251339121","DOIUrl":"10.1177/15347354251339121","url":null,"abstract":"<p><p>Chemotherapy-induced peripheral neuropathy (CIPN) has a markedly deleterious impact on a patient's quality of life. It manifests as pain, paresthesia, numbness, and weakness, particularly in the context of cisplatin (CDDP), a widely utilised chemotherapeutic agent renowned for its pronounced peripheral nerve toxicity. Trichosanthes kirilowii Maxim. (Cucurbitaceae, TK) and cucurbitacin D(CucD), its bioactive compound, have been demonstrated to possess anti-tumour, anti-inflammatory, and antioxidant properties. However, their potential to alleviate CIPN has not been fully exploredyet. The present study evaluated effectiveness of TK and CucD in mitigating CDDP-induced neuropathic pain using both cellular and animal models. CDDP, TK extracts (TKD and TKE), and CucD dose-dependently reduced viability and apoptosis of PC12 cells. Conversely, pre-treatment with TKD, TKE, and CucD exhibited significant protective effects against CDDP-induced cytotoxicity, preserving cell viability and morphology while enhancing neurite outgrowth. In vivo, administration of CDDP resulted in the development of mechanical allodynia and thermalhyperalgesia in rats. However, treatment with TKD and TKE led to a notable improvement in pain threshold and a reduction in hyperalgesia, while CucD demonstrated less pronounced effects. Although body weight was reduced in the CDDP-treated group, it was not significantly mitigated bytreatments. In conclusion, results of this study indicate that TKD, TKE, and CucD have the potential to alleviate CDDP-induced neuropathic pain by protecting against cell damage, promoting neuriteregeneration, and improving pain responses in animal models. Further investigation into TK and CucD as therapeutic options for managing CIPN is warranted.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"24 ","pages":"15347354251339121"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12089711/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Moxibustion Treatment, Alongside Conventional Western and Chinese Herbal Medical Therapies, May Improve Survival in Stage-IV Pulmonary Adenocarcinomas in a Dosage-Dependent Manner: A Prospective Observational Study With Propensity Score Analysis.","authors":"Hegen Li, Veronika Lindberg, Lihua Zhu, Xiange Huang, Jiali Feng, Jan P A Baak","doi":"10.1177/15347354251342739","DOIUrl":"10.1177/15347354251342739","url":null,"abstract":"<p><strong>Background: </strong>25% to 30% of primary stage IV pulmonary adenocarcinomas (PUAD-IV) die within 3 months. Many ≥3 months survivors at long follow-up are alive with disease (AWD). Platinum-based chemotherapy (PBC), tyrosine kinase inhibitors- targeted therapy (TKI-TT), and Chinese herbal medicines (oral CHM) improve prognosis. In China, moxibustion treatment (Moxa) is also used, without prognostic proof.</p><p><strong>Methods: </strong>Prospective observational Moxa evaluation in 412 first-onset consecutive PUAD-IV performance score 0 to 1 patients with 3 to 120 months follow-up. All received oral CHM with PBC, TKI-TT, or PBC + TKI-TT. Moxa was given as indicated at the start of the treatment (and eventually adapted in the follow-up period by de novo development) of well-established TCM syndromes and symptoms. Survival was analyzed using Kaplan-Meier and Cox regression. Propensity score analysis (PSA) with matching and inverse probability of treatment weighting (IPTW) were used to adjust for baseline covariate imbalances.</p><p><strong>Results: </strong>Of 412 patients, 117 received no Moxa, 239 had 1 to 4 treatments, and 56 received >4 treatments alongside conventional treatments. Tumor-Node-Metastasis (TNM) stage IVB and male sex increased dead of disease (DOD)-risk, while TKI-TT, ≥4 Chemotherapy cycles, and Moxa improved survival (<i>P</i> < .05). Median survival (MST): Reference group (PBC + CHM) 20.0 months; Moxa 32.0; TKI-TT 33.0; TKI-TT+1-4 Moxa 33.0; TKI-TT+>4 Moxa 40.0 months (all <i>P</i> < .05). Cox regression indicated a dosage-dependent Moxa effect (<i>P</i> = .0004). Restricted Mean Survival Time (RMST) at 36 months favored >4 Moxa+TKI-TT over TKI-TT (+6.2 months, <i>P</i> = .01). PSA confirmed results were not due to baseline covariate imbalance.</p><p><strong>Conclusions: </strong>Moxibustion may dosage-dependently improve survival in PUAD-IV, both in TKI- and non-TKI-treated patients. Randomized clinical trials (RCT) are needed to confirm this.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"24 ","pages":"15347354251342739"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179449/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144333071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}